Paul Tudor Jones Tarsus Pharmaceuticals, Inc. Transaction History
Tudor Investment Corp Et Al
- $25.1 Billion
- Q4 2024
A detailed history of Paul Tudor Jones (Tudor Investment Corp Et Al) transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Tudor Investment Corp Et Al holds 13,880 shares of TARS stock, worth $697,053. This represents 0.0% of its overall portfolio holdings.
Number of Shares
13,880Holding current value
$697,053% of portfolio
0.0%Shares
3 transactions
Others Institutions Holding TARS
# of Institutions
199Shares Held
40.5MCall Options Held
72.7KPut Options Held
313K-
Black Rock Inc. New York, NY3.27MShares$164 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY3.24MShares$163 Million2.92% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.53MShares$127 Million5.35% of portfolio
-
Jennison Associates LLC2.5MShares$126 Million0.09% of portfolio
-
Tang Capital Management LLC San Diego, CA2.25MShares$113 Million9.38% of portfolio
About Tarsus Pharmaceuticals, Inc.
- Ticker TARS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,658,500
- Market Cap $1.34B
- Description
- Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...